

Annexin Pharmaceuticals

Empowering the body to fight vascular diseases

PRESS RELEASE

8 November 2022

First patient dosed in Annexin's Phase 2 study in retinal vein occlusion.

STOCKHOLM (8 November 2022) - Annexin Pharmaceuticals AB (publ) (Nasdaq First North Growth market) announces today that the first patient with retinal vein occlusion (RVO) has been dosed in the Company's Phase 2 clinical study with ANXV.

RVO is one of the most common causes of blindness. Authorized drugs for treatment of RVO are injected directly into the eye and have no direct effect on the blockage of blood vessels that causes the disease. By contrast, the Company's drug candidate ANXV, which is administered intravenously, has the potential to directly counteract the blockage of blood vessels as well as the retinal swelling and the inflammatory processes caused by RVO.

The Phase 2 study is placebo-controlled and is expected to involve approximately 20 patients at five trial centers in the United States. The study will evaluate the safety and tolerability of ANXV and endpoints related to vision and retinal function. Initial safety data from the study are expected to be available at the end of 2022 and efficacy data during the first half of 2023.

"Our hope is that ANXV will prove to be a safe and effective treatment for patients with RVO. ANXV has the potential to offer these patients a significantly better vision than they get with current medications," says Anna Frostegård, the Company's Chief Scientific and Medical Officer.

"The dosing of the first patient in our US-based Phase 2 study is a significant milestone for our company. We are now focusing on carrying out the study, and we hope for exciting results," says the Company's CEO, Anders Haegerstrand.



About Annexin Pharmaceuticals AB (publ)

Annexin Pharmaceuticals AB is a clinical stage biotechnology company world-leading in the Annexin A5 field for the treatment of various vascular diseases. The company's biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is primarily intended for short term treatment of patients with injuries and inflammation of the blood vessels. The company has an extensive patent portfolio for the treatment of diseases that occur due to the damage and inflammation of the blood vessels. Annexin Pharmaceuticals has established and optimized a cell line for large-scale production of ANXV.

The Company is based in Stockholm, Sweden and listed on Nasdaq First North Growth Market, under the ticker ANNX. Redeye is the company's Certified Adviser.

For further information, please contact:

Anders Haegerstrand, CEO, tel +4670 - 575 50 37

The information was submitted for publication at 11:30 on 8 November 2022
